5 Publikationen
-
2023 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2968186Shao, S., Scholtz, L.-U., Gendreizig, S., Martínez-Ruiz, L., Florido, J., Escames, G., Schürmann, M., Hain, C., Hose, L., Mentz, A., Schmidt, P., Wang, M., Goon, P., Wehmeier, M., Brasch, F., Kalinowski, J., Oppel, F. & Sudhoff, H. (2023). Primary head and neck cancer cell cultures are susceptible to proliferation of Epstein-Barr virus infected lymphocytes. BMC Cancer, 23(1): 47. BioMed Central. doi:10.1186/s12885-022-10481-y.
-
2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2965718Oppel, F., Shao, S., Gendreizig, S., Kühnel, P., Przybycin, V., Hain, C., Schmidt, P., Schürmann, M., Goon, P., Niehaus, K., Kalinowski, J. & Sudhoff, H. (2022). Head and neck cancer cells can differentiate and resemble their tissue of origin (Cancer Research). Proceedings: AACR Annual Meeting 2022; April 8-13, 2022; New Orleans, LA (S. 111-111). Gehalten auf der AACR Annual Meeting 2022, American Association for Cancer Research (AACR). doi:10.1158/1538-7445.AM2022-111.
-
2022 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2967816Gendreizig, S., Neumann, J.M., Loganathan, L., Hose, L., Goon, P., Oppel, F., Brasch, F., Niehaus, K. & Sudhoff, H. (2022). P35 Spatial proteomics and metabolomics investigations in head & neck cancers. Oral Oncology, 134: 106164. Elsevier . doi:10.1016/j.oraloncology.2022.106164.
-
2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2967817Oppel, F., Gendreizig, S., Kühnel, P., Martínez-Ruiz, L., Shao, S., Schmidt, P., Hain, C., Schürmann, M., Hose, L., Pabla, H., Loganathan, L., Viyof Ful, F., Przybycin, V., Scholtz, L.-U., Brasch, F., Busche, T., Goon, P., Escames, G., Niehaus, K., Kalinowski, J. & Sudhoff, H. (2022). P28 Head and neck cancer cells differentiate resembling their tissue of origin (Oral Oncology). In Amsterdam University Medical Centers (Hrsg.), Abstracts of the 4th International Symposium on HPV Infection in Head and Neck Cancer Latest Advances in Biomarker-driven Management. Elsevier . doi:10.1016/j.oraloncology.2022.106159.
-
2022 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2965703Oppel, F., Shao, S., Gendreizig, S., Zimmerman, M.W., Schürmann, M., Viyof Ful, F., Goon, P., Chi, S.N., Aster, J.C., Sudhoff, H. & Look, A.T. (2022). p53 pathway inactivation drives SMARCB1-deficient p53-wildtype epithelioid sarcoma onset indicating therapeutic vulnerability through MDM2 inhibition. Molecular Cancer Therapeutics. American Association for Cancer Research (AACR). doi:10.1158/1535-7163.MCT-21-0770.